Capitolis Liquid Global Markets LLC Sells 93,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Capitolis Liquid Global Markets LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 55.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 75,000 shares of the biopharmaceutical company’s stock after selling 93,000 shares during the quarter. Capitolis Liquid Global Markets LLC owned approximately 0.07% of Regeneron Pharmaceuticals worth $42,170,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. CoreCap Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% in the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 3.5% during the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 21 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 21 shares during the period. MAI Capital Management increased its holdings in Regeneron Pharmaceuticals by 2.1% in the 3rd quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 21 shares during the period. Finally, Independence Bank of Kentucky raised its stake in shares of Regeneron Pharmaceuticals by 7.7% in the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 22 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.1%

REGN opened at $745.77 on Friday. The firm’s 50-day simple moving average is $769.73 and its 200-day simple moving average is $694.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market cap of $78.84 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 2.00 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $12.07 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an “overweight” rating and a $923.00 target price on the stock. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Finally, Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $802.27.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.